PTC Therapeutics, Inc. (PTCT)
$59.67-0.42%Close
SELLCRISIS · day 2
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $4.9B
- Beta
- 0.55
- P/E (TTM)
- -121.78
- Short % float
- 12.53%
- Days to cover
- 6.1
- SI change
- -5.9%
- 1W
- -5.63%
- 1M
- -9.11%
- vs SPY 1W
- -5.49%
- vs SPY 1M
- -11.61%
Industry peers
FMP comparable companies · ranked by market cap
- BBIOSELLBridgeBio Pharma, Inc.$12.8BRECOVERYQ 18$65.35+2.59%
- BMRNSELLBioMarin Pharmaceutical Inc.$10.6BBEARQ 12$54.80+1.40%
- KRYSSELLKrystal Biotech, Inc.$9.8BBEARQ 46$331.61+2.97%
- IONSSELLIonis Pharmaceuticals, Inc.$7.5BCRISISQ 8$45.28+0.76%
- DYNSELLDyne Therapeutics, Inc.$3.1BCRISISQ 3$16.64-1.70%
- SRPTSELLSarepta Therapeutics, Inc.$1.9BCRISISQ 13$17.85+1.94%
- RAREBUYUltragenyx Pharmaceutical Inc.$1.5BRECOVERYQ -6$15.48-0.13%
- WVESELLWave Life Sciences Ltd.$682MCRISISQ 7$3.46-1.59%
- SLDBSELLSolid Biosciences Inc.$676MCRISISQ -13$6.87-6.01%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 53
- VALUE
- 14
- GROWTH
- 60
- GARP
- 62
- TYPE
- Growth Compounder
Composite of Value · Growth · GARP
ROIC13.0%
REV YoY-
ROE21.7%
EPS YoY-
ROA-1.2%
GROSS82
OP12
NET-4
[VALUATION]
P/E TTM-121.78
P/E FWD27.24
SECTOR PE20.48
INDUSTRY PE13.99
P/B-29.95
P/FCF-
EV/EBITDA26.66
EV/EBIT-
PEG0.85
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO3.39
ND/EBITDA-
BETA0.55
Company news
FAQ
- What is LOPJLB’s current signal on PTCT?
- LOPJLB’s latest quantitative signal on PTC Therapeutics, Inc. (PTCT) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is PTCT in?
- PTC Therapeutics, Inc. (PTCT) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does PTC Therapeutics, Inc. (PTCT) do?
- PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of developmentâfrom early research and preclinical studies to clini…